COVID-19 infection: The prospects of pharmacotherapy

被引：9

作者：

Patil, Shashank M. ^{[1
]}

Kumari, V. B. Chandana ^{[1
]}

Shirahatti, Prithvi S. ^{[2
]}

Sujay, S. ^{[1
]}

Tejaswini, M. ^{[1
]}

Ranganath, Lakshmi V. ^{[3
]}

Jayanthi, M. K. ^{[4
]}

Ramu, Ramith ^{[1
]}

机构：

[1] JSS Acad Higher Educ & Res, Sch Life Sci, Dept Biotechnol & Bioinformat, Mysuru 570015, Karnataka, India

[2] Teresian Coll, Dept Biotechnol, Mysuru, Karnataka, India

[3] Natl Inst Engn, Dept Chem, Mysuru, Karnataka, India

[4] JSS Acad Higher Educ & Res, Dept Pharmacol, JSS Med Coll, Mysuru, Karnataka, India

来源：

INTERNATIONAL JOURNAL OF HEALTH AND ALLIED SCIENCES | 2020年 / 9卷

关键词：

Coronavirus disease 2019; diagnosis; SARS-CoV-2; therapeutics; transmission;

D O I：

10.4103/ijhas.IJHAS_89_20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The disastrous outbreak of coronavirus disease 2019 (COVID-19) has triggered the investigation of several therapeutic options following the redundancy of specific drugs against it. The virus possesses advanced molecular mechanisms to effectively invade the host cell compared to its counterparts. It results in a seamless and coherent infection and transmission, attributing to its enhanced pathogenicity. The drugs that are currently being employed against COVID-19 inhibit the viral load in different stages of infection, including host cell-virus interaction, viral entry into the host cell, and viral replication inside the host including genome replication and polypeptide chain production. This commentary emphasizes the pharmacotherapeutic options available from the perspective of viral life cycle and pathogenicity.

引用

页码：111 / 113

页数：3

共 14 条

[1]

[Anonymous], 2020, WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020

[2] Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 [J].

Barlow, Ashley ;

Landolf, Kaitlin M. ;

Barlow, Brooke ;

Yeung, Siu Yan Amy ;

Heavner, Jason J. ;

Claassen, Cassidy W. ;

Heavner, Mojdeh S. .

PHARMACOTHERAPY, 2020, 40 (05) :416-437

[3] Chest CT Findings in Coronavirus Disease 2019 (COVID-19): Relationship to Duration of Infection [J].

Bernheim, Adam ;

Mei, Xueyan ;

Huang, Mingqian ;

Yang, Yang ;

Fayad, Zahi A. ;

Zhang, Ning ;

Diao, Kaiyue ;

Lin, Bin ;

Zhu, Xiqi ;

Li, Kunwei ;

Li, Shaolin ;

Shan, Hong ;

Jacobi, Adam ;

Chung, Michael .

RADIOLOGY, 2020, 295 (03) :685-691

[4] Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance [J].

Choudhary, R. ;

Sharma, A. K. .

NEW MICROBES AND NEW INFECTIONS, 2020, 35

[5] Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19 [J].

Damle, Bharat ;

Vourvahis, Manoli ;

Wang, Erjian ;

Leaney, Joanne ;

Corrigan, Brian .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (02) :201-211

[6] Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics) [J].

Hamid, Saima ;

Mir, Mohammad Yaseen ;

Rohela, Gulab Khan .

NEW MICROBES AND NEW INFECTIONS, 2020, 35

[7] Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19 [J].

Khalili, Jahan S. ;

Zhu, Hai ;

Mak, Nga Sze Amanda ;

Yan, Yongqi ;

Zhu, Yi .

JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (07) :740-746

[8] Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options [J].

McCreary, Erin K. ;

Pogue, Jason M. .

OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (04)

[9] Novel Coronavirus: Current Understanding of Clinical Features, Diagnosis, Pathogenesis, and Treatment Options [J].

Mungroo, Mohammad Ridwane ;

Khan, Naveed Ahmed ;

Siddiqui, Ruqaiyyah .

PATHOGENS, 2020, 9 (04)

[10] COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses [J].

Shereen, Muhammad Adnan ;

Khan, Suliman ;

Kazmi, Abeer ;

Bashir, Nadia ;

Siddique, Rabeea .

JOURNAL OF ADVANCED RESEARCH, 2020, 24 :91-98

← 1 2 →